The efficacy and safety of donafenib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective study.

医学 肝细胞癌 佐剂 回顾性队列研究 切除术 辅助治疗 外科 肿瘤科 内科学 放射科 化疗
作者
Yongjun Chen,Yang Yuchen,Ma Di,Junqing Wang,Yan-Cen Lu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl) 被引量:1
标识
DOI:10.1200/jco.2025.43.16_suppl.e16272
摘要

e16272 Background: The recurrence rate of hepatocellular carcinoma (HCC) after hepatectomy is still high. Despite the advance in treatment , there is no globally recognized standard adjuvant therapy for HCC after radical resection.Exploration of treatment strategies that are both efficacious and safe has been extensively performed in the recent years. This study aimed to evaluate the efficacy and safety of donafenib combined with TACE as adjuvant therapy in HCC patients with high-risk recurrence factors after radical resection. Methods: This single-center retrospective study enrolled primary HCC patients with high-risk recurrence factors who underwent surgical resection at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from August 2020 to October 2024, All patients exhibited at least one of the following high-risk recurrence factors:preoperative AFP level>400ng/mL, the number of tumors≥2, the maximum diameter of tumors>5cm, Edmondson stage III~IV, microvascular invasion (MVI) and satellite lesions. Patients received adjuvant therapy of donafenib combined with TACE after surgery. Patients’ demographic characteristics, etiological characteristics, 1-year recurrence-free survival rate (RFSR), overall survival rate (OSR), and treatment-related safety were analyzed. The primary endpoint was 1-year RFSR. Secondary endpoints included OSR and safety. Results: A total of 44 patients were enrolled with a median age of 61.5 (range 26-85). 26 patients (59.1%) in BCLC stage A and 18 patient (40.9%) in BCLC stage B. 35 patients (70.5%) were co-infected with HBV. 36 patients (81.8%) had Child-Pugh scores of A, 8 patients (18.2%) had Child-Pugh scores of B. All 44 patients had ECOG PS scores of 0. All patients exhibited a high risk factor of recurrence at least (preoperative AFP level within 400/above 400 ng/mL, 38/6; number of tumors single/multiple, 20/24; the maximum diameter of tumors within 5.0/above 5.0 cm, 25/19; Edmondson stage Ⅰ~Ⅱ/III~IV, 12/32; MVI yes/no, 25/19; satellite nodules yes/no, 3/41). All patients received at least one TACE treatment after surgery. The initial dose of donafenib was 100mg bid. The median follow-up time was 23 months (95%CI: 21.91-27.46), 26 patients relapsed and 5 patients died. The median RFS was 16 months (95% CI: 14.33-18.67), the 1-year RFSR was 81.8%, and the 1-year OSR was 97.7%. 36 (81.8%) patients had at least one treatment-related AE (TRAE). Grade 3 and 4 TRAEs all occurred in 4 (9.1%) patients, no grades 5 were reported. The most Common TRAEs included hand-foot syndrome (47.7%), hypertension (36.4%), and rash (29.5%). Conclusions: Donafenib combined with TACE was used for adjuvant therapy in patients with high-risk recurrence of HCC, which has a high 1-year RSFR and exhibited favorable safety. This finding deserves further exploration.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Uyz完成签到,获得积分10
1秒前
yu完成签到,获得积分10
1秒前
天天快乐的应助被adai007采纳,获得10
1秒前
1秒前
polarisla完成签到,获得积分10
1秒前
杨媛发布了新的文献求助10
2秒前
hmm萌萌哒哒完成签到,获得积分10
2秒前
小吴完成签到 ,获得积分10
3秒前
Totoya完成签到,获得积分10
3秒前
大方雪卉完成签到,获得积分10
3秒前
如果Ta完成签到,获得积分10
3秒前
爱哥哥的妹妹关注了科研通微信公众号
3秒前
一区的神完成签到,获得积分10
3秒前
imEda完成签到,获得积分10
3秒前
灶鲜森发布了新的文献求助10
4秒前
夏冰雹完成签到 ,获得积分10
4秒前
4秒前
ff完成签到,获得积分10
4秒前
木林森幻完成签到,获得积分10
4秒前
瑞一杯小黄油拿铁完成签到,获得积分10
4秒前
章鱼哥发布了新的文献求助30
5秒前
科研通AI65的应助被canhui采纳,获得10
5秒前
DOC_XIONG的应助被canhui采纳,获得10
5秒前
zhyclover完成签到,获得积分10
5秒前
cai完成签到 ,获得积分10
6秒前
6秒前
6秒前
王欣瑶完成签到 ,获得积分10
7秒前
小朵完成签到 ,获得积分10
7秒前
DuDu完成签到,获得积分10
7秒前
Cr的应助被研友来科研啊采纳,获得10
8秒前
xiakui完成签到,获得积分10
9秒前
Youdge完成签到,获得积分0
9秒前
yu完成签到,获得积分10
10秒前
baozeNG发布了新的文献求助10
10秒前
chiyu完成签到,获得积分10
10秒前
csu_zs完成签到,获得积分10
11秒前
传奇3的应助被王电催化采纳,获得10
11秒前
11秒前
fairytaler的应助被他说采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105